Who is candidate for CRS and HIPEC?

Clinical features suggesting a favorable outcome for use of cytoreductive surgery and hyperthermic perioperative chemotherapy in patients with peritoneal metastases:

1. General medical condition compatible with survival and recovery from the procedure.
2. Clinical information regarding the peritoneal metastases compatible with a complete or near complete cytoreduction.
3. Relative sparing of the small bowel and colon.
4. Absence of disease outside the abdomen/pelvis.
5. If hepatic metastases are present, they are limited, compatible with wedge resection.
6. Absence of disease within the porta hepatis.
7. With a high-grade malignancy, a low or moderate peritoneal cancer index.
8. A-symptomatic patient.

Clinical features suggesting cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should NOT be recommended include:

1. Poor performance status.
2. Rapid progression of a high-grade disease process.
3. Low likelihood of a response to perioperative chemotherapy.
4. Prior abdominal or pelvic radiation therapy.
5. Asymptomatic from peritoneal metastases.